Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus

Show simple item record

dc.contributor.author Wihastuti, Titin Andri
dc.contributor.author Aini, Fitria Nugraha
dc.contributor.author Tjahjono, Cholid Tri
dc.contributor.author Sulfia, Yuni Hendrati
dc.contributor.author Sholichah, Zuhrotus
dc.contributor.author Heriansyah, Teuku
dc.date.accessioned 2021-10-14T01:43:25Z
dc.date.available 2021-10-14T01:43:25Z
dc.date.issued 2019-11-01
dc.identifier.issn 503–508
dc.identifier.uri https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830380/
dc.identifier.uri http://repository.unisma.ac.id/handle/123456789/2032
dc.description [ARCHIVES] Copyright Article from: Vascular Health and Risk Management (US National Library of Medicine National Institutes of Health) en_US
dc.description.abstract Purpose The aim of this study is to prove that type 2 diabetes mellitus can induce increasing inflammation marker in renal and that the provision of darapladib as Lp-LA2 Inhibitor agents can inhibit inflammation that were measured from the expression of IL-1B and IL-6- type cytokine in renal. This study also discusses the correlation between IL-1B and IL-6- type cytokine expression in renal. Methods Thirty Sprague-Dawley (SD) rats were divided into three main groups; those are negative control group (NC), Type 2 Diabetes Mellitus group (T2DM) given high fat diet (HFD) with streptozotocin intraperitoneal injection (35mg/kg BW) and diabetes mellitus + darapladib group (DM + DP). Each group was treated within two serial treatment time: 8 weeks and 16 weeks. Expressions of IL-1B and IL-6- type cytokine in renal were the markers that we measured by immunofluorosense method. Results The administration of darapladib can significantly decrease the expression of IL-1B- type cytokine (p ANOVA = 0.029, p < 0.005) measured in rats’ renal both at weeks 8 and 16 in the T2DM group. The Expression of IL-6- type cytokine also showed a significant difference after treated with darapladib both at weeks 8 and 16 in T2DM group with p-value of ANOVA = 0.033, p < 0.005. The Pearson correlation showed a strong correlation (linear regression value was r2 = 0.743). Conclusion Our results show that atherosclerosis caused by inflammation in renal T2DM SD rats could be inhibited by the administration of darapladib. en_US
dc.language.iso en en_US
dc.publisher US National Library of Medicine National Institutes of Health en_US
dc.relation.ispartofseries Vascular Health and Risk Management;
dc.subject IL-1B- type cytokine en_US
dc.subject IL-6- type cytokine en_US
dc.subject kidney organ en_US
dc.subject diabetes mellitus type 2 en_US
dc.subject darapladib en_US
dc.title Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus en_US
dc.type Article en_US


Files in this item

Icon
Name: dr. Fitria Nugraha-2- ...
Size: 1.559Mb
Format: PDF
Description: Document
View/Open

This item appears in the following Collection(s)

Show simple item record

Kolom Pencarian


Browse

My Account